Unknown

Dataset Information

Potential role of nicotinamide analogues against SARS-COV-2 target proteins.


ABSTRACT:

Background and objective

Coronavirus 2019 (COVID-19) is caused by 'severe acute respiratory syndrome coronavirus 2' (SARS-CoV-2), first reported in Wuhan, China in December 2019, which eventually became a global disaster. Various key mediators have been reported in the pathogenesis of COVID-19. However, no effective pharmacological intervention has been available to combat COVID-19 complications. The present study screens nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) as potential inhibitors of this present generation coronavirus infection using an in-silico approach.

Materials and methods

The SARS-CoV-2 proteins (nucleocapsid, proteases, post-fusion core, phosphatase, endoriboruclease) and ACE-2 protein were selected. The 2D structure of nicotinamide ribon

SUBMITTER: Arora MK 

PROVIDER: S-EPMC8482651 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature